SCHEMBL6401957

SCHEMBL6401957

CC(C(=O)c1cc(O)ccc1OP(=O)(O)O)c1cccc(O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
PPARG P37231 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 2/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
PDE3A Q14432 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HIF1A Q16665 3/20 0.36
LMNA P02545 1/20 0.36
INPPL1 O15357 4/20 0.36
INPP5A Q14642 4/20 0.36
INPP5B P32019 2/20 0.36
ADRB1 P08588 1/20 0.36
MIF P14174 1/20 0.36
HTR2A P28223 1/20 0.36
ADRA1A P35348 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396423 0.90 MEN1 (0.43) MEN1CYP3A4MAPTPPARGKMT2A
SCHEMBL6398724 0.88 MAPT (0.49) MEN1CYP3A4MAPTPPARGKMT2A
SCHEMBL6398043 0.84 LMNA (0.42) MEN1MAPTKMT2AKDM4EUSP2
SCHEMBL6399853 0.81 ABCB1 (0.39) KDM4EUSP2ALDH1A1HPGDPDE3A
SCHEMBL6396962 0.81 INPPL1 (0.39) MEN1CYP3A4MAPTPPARGKMT2A
SCHEMBL6399197 0.80 MAPT (0.40) MEN1CYP3A4MAPTPPARGKMT2A
SCHEMBL6394470 0.80 MEN1 (0.36) MEN1CYP3A4MAPTPPARGKMT2A
SCHEMBL6396095 0.77 MAPT (0.43) MEN1CYP3A4MAPTPPARGKMT2A
SCHEMBL7622196 0.77 TYR (0.41) KDM4EHIF1ALMNAINPPL1INPP5A
SCHEMBL6401071 0.77 MEN1 (0.52) MEN1CYP3A4MAPTPPARGKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885CYP3A4 1053/4885MAPT 3461/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MEN1 2179/4885CYP3A4 1301/4885MAPT 3363/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885CYP3A4 1053/4885MAPT 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.